Verizon to cut 15,000 jobs amid growing competition pressures - WSJ
Investing.com -- AstraZeneca Plc can absorb the financial impact of its recent US drug pricing agreement next year, according to Chief Financial Officer Aradhana Sarin.
The UK drugmaker struck a deal with President Donald Trump in October that will see the company reduce prices for some medicines and launch new products in the US at the same cost as in other wealthy countries.
"We believe we can absorb the impact of this transaction," Sarin told reporters Thursday, citing the company’s broad revenue base and wide portfolio. The agreement has been factored into AstraZeneca’s 2026 budget planning.
AstraZeneca became the second pharmaceutical company to reach a drug pricing agreement with the Trump administration, which exempts the firm from tariffs for three years. The company did not disclose specific financial details when the deal was announced.
CEO Pascal Soriot also addressed broader pricing concerns, noting that even with a 25% increase to the threshold used to determine cost-effectiveness in the UK, a lower rebate rate is also needed. Rebates are payments drugmakers return to the National Health Service.
Soriot warned that if countries fail to properly value pharmaceutical innovation and "things continue to deteriorate," some regions might only be able to provide their citizens with generic medicines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.